<DOC>
	<DOCNO>NCT01652690</DOCNO>
	<brief_summary>The objective prospective , observational study Czech Republic Slovakia describe per country characteristic woman treat denosumab routine clinical practice clinical management patient first 2 year treatment . In addition , study aim collect safety data real-life clinical practice setting adverse drug reaction ( ADRs ) serious ADRs .</brief_summary>
	<brief_title>Prospective Observational Study Describe Characteristics Management Patients Treated With Denosumab ( Prolia® ) Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Inclusion Criteria Women clinical diagnosis postmenopausal osteoporosis Decision make treat denosumab 60 mg every 6 month Have receive first injection denosumab within 8 week prior enrol study . Appropriate write informed consent obtain ( require per local country regulation ) Exclusion Criteria Participating ongoing participate previous denosumab clinical trial Participation clinical device trial last 6 month Contraindicated treatment Prolia® accord approve applicable local product label . Subject kind disorder , opinion investigator , may compromise ability subject give write informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>